lysosome

Type: Keyphrase

Name: lysosome

First reported 1 hour ago - Updated 1 hour ago - 1 reports

FDA Designation for Synageva Candidate - Analyst Blog

Synageva BioPharma Corp.$ ( GEVA ) recently announced that it has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for sebelipase alfa.Synageva is developing sebelipase alfa for the treatment of early onset lysosomal ... [Published Nasdaq - 1 hour ago]

Entities: FDA Food & Drug Administration, Ibrutinib, non-small cell lung cancer, lymphoma, Novartis AG

First reported May 21 2013 - Updated May 21 2013 - 1 reports

BioMarin Pharmaceutical Inc

Buyers Accumulate Shares of BioMarin...

One of today's notable stocks on the rise is BioMarin Pharmaceutical (NASDAQ:BMRN), up 1.4% to $63.33. The Dow is trading fractionally higher to 15,337 and the S&P is currently trading fractionally lower to 1,664. BioMarin Pharmaceutical has overhead ... [Published Financial News Network online - May 21 2013]

Entities: BioMarin Pharmaceutical Inc, Stocks, fractionation, Enzyme

First reported May 20 2013 - Updated May 20 2013 - 6 reports

FDA Food & Drug Administration

FDA grants 'breakthrough' designation to Synageva drug

(Boston Herald - McClatchy-Tribune Information Services via COMTEX News Network) -- Synageva BioPharma Corp., a Lexington-based biopharmaceutical company that develops drugs for rare diseases, said today that the U.S. Food and Drug Administration has ... [Published PredictWallStreet - May 20 2013]

Entities: FDA Food & Drug Administration, Drugs, lysosome

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Callidus Biopharma Closes on $4.6 million in Series A Financing to Develop Orphan Disease Therapies [Professional Services Close - Up]

Callidus Biopharma, Inc., a development-stage biotechnology company focused on creating breakthrough biologic drugs for a range of orphan diseases, announced that it has closed on $4.6 million in Series A financing led by two strategic investors.In a ... [Published Pharmacy Choice - May 20 2013]

Entities: Enzyme, lysosome, Protein, Drugs

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease

by Max C. Liebau, Fabian Braun, Katja Höpker, Claudia Weitbrecht, Valerie Bartels, Roman-Ulrich Müller, Susanne Brodesser, Moin A. Saleem, Thomas Benzing, Bernhard Schermer, Markus Cybulla, Christine E. KurschatFabry’s disease results from an inborn error ... [Published Elites TV - May 19 2013]

Entities: lysosome, Kinase, Kidney, Proteinuria, Transduction

First reported May 18 2013 - Updated May 18 2013 - 1 reports

DRAM1 Regulates Autophagy Flux through Lysosomes

by Xing-Ding Zhang, Lin Qi, Jun-Chao Wu, Zheng-Hong QinWe have previously reported that the mitochondria inhibitor 3-nitropropionic acid (3-NP), induces the expression of DNA damage-regulated autophagy modulator1 (DRAM1) and activation of autophagy in ... [Published Elites TV - May 18 2013]

Entities: lysosome, Flux, sirna

First reported May 17 2013 - Updated May 17 2013 - 1 reports

2013-05-17 - Improving our understanding of lysosomal disorders

Under normal physiological conditions, most of the body's cellular clearing processes occur in a specialised organelle, the lysosome. Impairment of lysosomal function leads to a variety of pathologies, usually associated with neurodegeneration.Lysosomal ... [Published Cordis - May 17 2013]

Entities: lysosome, Phenotype, Metabolite

First reported May 17 2013 - Updated May 17 2013 - 1 reports

A Possible Biomarker for Senescent Cells

There are any number of techniques under development that allow individual cells to be destroyed provided that you can distinguish them from their neighbors: the challenge is in finding characteristic differences in the cells you want destroyed, such ... [Published Fight Aging! - May 17 2013]

Entities: Biomarker, lysosome, Oligosaccharides, Glycoprotein, Murine

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the scientific understanding of disease mechanisms at the molecular, genetic and genomic levelsThe National Human Genome Research ... [Published PMLive - May 17 2013]

Entities: Oncology, treatments, Patient, Philadelphia Chromosome, Iressa

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Biotech firm raises $4.6M

Callidus Biopharma Inc. raised $4.6 million in a private stock sale this week.The development-stage biotechnology company, which is based at Pennsylvania Biotech Center of Bucks County in Doylestown, Pa, is specializing in the development of biologic ... [Published Philadelphia Business Journal - May 16 2013]

Entities: Biotechnology, lysosome, Drugs

First reported May 15 2013 - Updated May 15 2013 - 2 reports

Ultragenyx Pharmaceuticals Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)

Staying up-to-date has never been simpler. Sign up for the today! NOVATO, Calif., May 15, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today ... [Published BioSpace - May 15 2013]

Entities: Mucopolysaccharidosis, lysosome, Enzyme

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Cellular Garbage Disposals Clean Up

When proteins enter the proteasome, they’re chopped into bits for re-use.CREDIT: Office of Biological and Environmental Research of the U.S. Department of Energy Office of Science.Cells rely on garbage disposal systems to keep their interiors neat and ... [Published LiveScience.com - May 15 2013]

Entities: lysosome, Protein, Enzyme, Cancer, National institutes of Health

Quotes

"That's the reason why it was so important to find the receptor" Hall says. "Then we can actually do some pharmacology."

Finding a family for a pair of orphan receptors in the brain [Published Brightsurf Science News - 1 hour ago]

"Another novel compound of this invention comprises the structure:"

Patent Application Titled "Fluorescent Dyes" Published Onlin. . . [Published Equities.com - 2 hours ago]

More Content

sort by: Date \| Relevance
Finding a family for a pair of orphan receptors... [Published Brightsurf Science News - 1 hour ago]
FDA Designation for Synageva Candidate - Analys... [Published Nasdaq - 1 hour ago]
Patent Application Titled "Fluorescent Dyes" Pu... [Published Equities.com - 2 hours ago]
Synageva's Sebelipase Alfa Receives Breakthroug... [Published Drugs.com - 13 hours ago]
Amicus Therapeutics' CEO Presents at 2013 UBS G... [Published Seeking Alpha - 22 hours ago]
Nilotinib Enhances Toxic Protein Removal from P... [Published Biotech Daily - May 21 2013]
BioMarin Pharmaceutical Inc. Presents at UBS Gl... [Published Seeking Alpha - May 21 2013]
Buyers Accumulate Shares of BioMarin... [Published Financial News Network online - May 21 2013]
Speakers offer perspectives about the role of g... [Published National Human Genome Research Institute - May 21 2013]
Apoptosis: Investigators at Weizmann Institute ... [Published NewsRX - May 21 2013]
FDA grants 'breakthrough' designation to Synage... [Published PredictWallStreet - May 20 2013]
FDA grants ‘breakthrough’ designation to Synage... [Published Boston Herald - May 20 2013]
FDA bestows 'Breakthrough Therapy' status to dr... [Published FierceBiotech - May 20 2013]
Sangamo Biosciences Inc Announces New Data From... [Published Reuters - May 20 2013]
Synageva drug candidate gets FDA’s ‘breakthroug... [Published Boston Globe - May 20 2013]
Synageva Reports FDA Grants Breakthrough Therap... [Published RTTNews.com - May 20 2013]
Synageva's Sebelipase Alfa Receives Breakthroug... [Published Benzinga.com - May 20 2013]
Synageva's Sebelipase Alfa Receives Breakthroug... [Published Business Wire - May 20 2013]
Sangamo BioSciences Presents New Data From In V... [Published ADVFN UK - May 20 2013]
Sangamo BioSciences Presents New Data From In V... [Published TickerTech.com - May 20 2013]
Synageva's Sebelipase Alfa Receives Breakthroug... [Published Business Wire Health News - May 20 2013]
Callidus Biopharma Closes on $4.6 million in Se... [Published Pharmacy Choice - May 20 2013]
Tissue matrices comprising placental stem cells [Published PharmCast - May 19 2013]
Dysregulated Autophagy Contributes to Podocyte ... [Published Elites TV - May 19 2013]
DRAM1 Regulates Autophagy Flux through Lysosomes [Published Elites TV - May 18 2013]
2013-05-17 - Improving our ... [Published Cordis - May 17 2013]
Stocks in Focus (Celldex Therapeutics, BioMarin... [Published SBWire - May 17 2013]
A Possible Biomarker for Senescent Cells [Published Fight Aging! - May 17 2013]
Payer focus in the personalised world of oncolo... [Published PMLive - May 17 2013]
Biotech firm raises $4.6M [Published Philadelphia Business Journal - May 16 2013]